Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone

Abstract

Combining E4 15 mg with DRSP 3 mg resulted in a COC with a different metabolic profile in comparison to EE-containing products. The clinical relevance of these findings needs to be further assessed, using clinical endpoints to establish the safety profile of this new COC.